This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Measurement of Kidney Blood Flow and Oxygen Levels by MRI

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Michael Rocco, Wake Forest University Health Sciences
ClinicalTrials.gov Identifier:
NCT01318967
First received: March 18, 2011
Last updated: January 23, 2017
Last verified: January 2017
March 18, 2011
January 23, 2017
October 2010
June 2012   (Final data collection date for primary outcome measure)
Measurement of Renal Blood Flow of the Kidney by the PAH Method [ Time Frame: Renal blood flow is estimated over 1 hour by PAH ]
Renal blood flow is estimated by the PAH method.
Comparison of renal blood flow (RBF) by PAH and MRI [ Time Frame: RBF measured over 1 hour by PAH and 30 minutes by MRI (day 1) ]
Complete list of historical versions of study NCT01318967 on ClinicalTrials.gov Archive Site
Measurement of Regional Blood Oxygenation by MRI [ Time Frame: One measure after furosemide (day 1) ]
Estimate of renal blood flow by using MRI scans before and after the administration of furosemide
Measurement of Regional Blood Oxygenation by MRI [ Time Frame: One measure before and after furosemide (day 1) ]
Not Provided
Not Provided
 
Measurement of Kidney Blood Flow and Oxygen Levels by MRI
MRI for the Non-invasive Determination of Renal Blood Flow and Renal Oxygenation
Comparison of renal blood flow measurements by PAH clearance and MRI
The traditional measurement of renal blood flow in ml/min involves the collection of multiple blood and urine samples after an infusion of a drug called para-aminohippurate (PAH) is given. In this study, the investigators determine the ability of MRI to estimate renal blood flow. The primary hypothesis is that renal blood flow as measured by PAH clearance is similar to renal blood flow as estimated by MRI. The measurements by PAH clearance and MRI are both performed on the same day.
Interventional
Not Provided
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Diagnostic
Chronic Kidney Disease
  • Drug: Furosemide
    Renal blood flow is measured after the administration of 20 mg of furosemide during MRI scan only.
    Other Name: Lasix
  • Other: Placebo
  • Placebo Comparator: PAH
    PAH measure of renal blood flow is first performed on subjects prior to administration of furosemide
    Intervention: Other: Placebo
  • Active Comparator: MRI after furosemide
    After the PAH measurement is complete, subjects receive 20 mg furosemide and undergo BOLD MRI to estimate renal blood flow
    Intervention: Drug: Furosemide
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
10
June 2013
June 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

In this study, the investigators will enroll 16 men and women aged ≥ 18 years with Stage II - V chronic kidney disease (CKD). In addition, the investigators will enroll 4 subjects with a glomerular filtration rate (GFR) of greater than 60 ml/min who do not have any evidence of CKD.

Exclusion Criteria:

This study excludes those not suitable for MRI or for the interventional pharmacologic procedures.

Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01318967
0537GCRC
No
Not Provided
Not Provided
Michael Rocco, Wake Forest University Health Sciences
Wake Forest University
Not Provided
Principal Investigator: Michael Rocco, MD Wake Forest University Health Sciences
Wake Forest University Health Sciences
January 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP